Eton Pharmaceuticals, Inc. Intangible Assets, Net (Excluding Goodwill)
Eton Pharmaceuticals, Inc. (ETON) had Intangible Assets, Net (Excluding Goodwill) of $45.68 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-13
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $45.68M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $43.74M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $30.88M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $31.88M.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2026-06-30 | $45.68M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $43.74M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $30.88M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $31.88M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $32.88M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $33.88M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $34.88M 10-K · filed 2026-03-19 |
| 2024-09-30 | $5.85M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $6.12M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $6.39M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $4.74M 10-K · filed 2025-03-18 |
| 2023-09-30 | $4.21M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.39M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $4.57M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $4.75M 10-K · filed 2024-03-14 |
| 2022-09-30 | $4.97M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $3.11M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $4.24M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $3.62M 10-K · filed 2023-03-16 |
| 2021-09-30 | $463.00K 10-Q · filed 2021-11-16 |
| 2021-06-30 | $500.00K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $537.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $575.00K 10-K · filed 2022-03-16 |
| 2020-09-30 | $612.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $650.00K 10-Q · filed 2020-08-12 |
| 2020-03-31 | $688.00K 10-Q · filed 2020-05-14 |
| 2019-12-31 | $725.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |